36 results on '"Piscianz, Elisa"'
Search Results
2. Microglia activation and interaction with neuronal cells in a biochemical model of mevalonate kinase deficiency
- Author
-
Tricarico, Paola Maura, Piscianz, Elisa, Monasta, Lorenzo, Kleiner, Giulio, Crovella, Sergio, and Marcuzzi, Annalisa
- Published
- 2015
- Full Text
- View/download PDF
3. Lovastatin Dose-Dependently Potentiates the Pro-inflammatory Activity of Lipopolysaccharide Both In Vitro and In Vivo
- Author
-
Zanin, Valentina, Marcuzzi, Annalisa, Kleiner, Giulio, Piscianz, Elisa, Monasta, Lorenzo, Zacchigna, Serena, Crovella, Sergio, and Zauli, Giorgio
- Published
- 2013
- Full Text
- View/download PDF
4. The immunosuppressive effect of Wharton's jelly stromal cells depends on the timing of their licensing and on lymphocyte activation
- Author
-
Valencic, Erica, Piscianz, Elisa, Andolina, Marino, Ventura, Alessandro, and Tommasini, Alberto
- Published
- 2010
- Full Text
- View/download PDF
5. The effect of clodronate on a mevalonate kinase deficiency cellular model
- Author
-
Zanin, Valentina, Marcuzzi, Annalisa, Piscianz, Elisa, Vuch, Josef, Bianco, Anna Monica, Monasta, Lorenzo, Decorti, Giuliana, and Crovella, Sergio
- Published
- 2012
- Full Text
- View/download PDF
6. Defect in mevalonate pathway induces pyroptosis in Raw 264.7 murine monocytes
- Author
-
Marcuzzi, Annalisa, Piscianz, Elisa, Girardelli, Martina, Crovella, Sergio, and Pontillo, Alessandra
- Published
- 2011
- Full Text
- View/download PDF
7. In vivo detection of polyomaviruses JCV and SV40 in mesenchymal stem cells from human umbilical cords
- Author
-
Comar, Manola, Delbue, Serena, Zanotta, Nunzia, Valencic, Erica, Piscianz, Elisa, Del Savio, Rossella, Tesser, Alessandra, Tommasini, Alberto, and Ferrante, Pasquale
- Published
- 2014
- Full Text
- View/download PDF
8. Regulatory T-Cell Function Is Impaired in Celiac Disease
- Author
-
Granzotto, Marilena, dal Bo, Sara, Quaglia, Sara, Tommasini, Alberto, Piscianz, Elisa, Valencic, Erica, Ferrara, Fortunato, Martelossi, Stefano, Ventura, Alessandro, and Not, Tarcisio
- Published
- 2009
- Full Text
- View/download PDF
9. Population Pharmacokinetics of Intravenous Acyclovir in Oncologic Pediatric Patients.
- Author
-
Maximova, Natalia, Nisticò, Daniela, Luci, Giacomo, Simeone, Roberto, Piscianz, Elisa, Segat, Ludovica, Barbi, Egidio, and Di Paolo, Antonello
- Subjects
CHILD patients ,ACYCLOVIR ,DRUG monitoring ,PHARMACOKINETICS ,GLOMERULAR filtration rate - Abstract
Background: Acyclovir represents the first-line prophylaxis and therapy for herpes virus infections. However, its pharmacokinetics in children exposes them to the risk of ineffective or toxic concentrations. The study was aimed at investigating the population pharmacokinetics (POP/PK) of intravenous (IV) acyclovir in oncologic children. Methods: Patients (age, 8.6 ± 5.0 years, 73 males and 47 females) received IV acyclovir for prophylaxis (n = 94) and therapy (n = 26) under a therapeutic drug monitoring (i.e., minimum and maximal plasma concentrations, >0.5 and <25 mg/L, respectively). Plasma concentrations were fitted by nonlinear mixed effect modeling and a simulation of dosing regimens was performed. Findings were stratified according to an estimated glomerular filtration rate (eGFR) threshold of 250 ml/min/1.73 m
2 . Results: The final 1-compartment POP/PK model showed that eGFR had a significant effect on drug clearance, while allometric body weight influenced both clearance and volume of distribution. The population clearance (14.0 ± 5.5 L/h) was consistent across occasions. Simulation of standard 1-h IV infusion showed that a 10-mg/kg dose every 6 h achieved target concentrations in children with normal eGFR (i.e., ≤250 ml/min/1.73 m2 ). Increased eGFR values required higher doses that led to an augmented risk of toxic peak concentrations. On the contrary, simulated prolonged (i.e., 2 and 3-h) or continuous IV infusions at lower doses increased the probability of target attainment while reducing the risk of toxicities. Conclusion: Due to the variable pharmacokinetics of acyclovir, standard dosing regimens may not be effective in some patients. Prospective trials should confirm the therapeutic advantage of prolonged and continuous IV infusions [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
10. Immunomodulatory Drugs in Autoimmune Lymphoproliferative Syndrome (Alps)
- Author
-
Tommasini, Alberto, Valencic, Erica, Piscianz, Elisa, and Rabusin, Marco
- Published
- 2012
- Full Text
- View/download PDF
11. Differential action of 3-hydroxyanthranilic acid on viability and activation of stimulated lymphocytes
- Author
-
Piscianz, Elisa, Cuzzoni, Eva, De Iudicibus, Sara, Valencic, Erica, Decorti, Giuliana, and Tommasini, Alberto
- Published
- 2011
- Full Text
- View/download PDF
12. Impact of Methylmercury and Other Heavy Metals Exposure on Neurocognitive Function in Children Aged 7 Years: Study Protocol of the Follow-up.
- Author
-
Brumatti, Liza Vecchi, Rosolen, Valentina, Mariuz, Marika, Piscianz, Elisa, Valencic, Erica, Bin, Maura, Athanasakis, Emmanouil, D'Adamo, Pio, Fragkiadoulaki, Eirini, Calamandrei, Gemma, Dinckol, Öykü, Barbone, Fabio, and Ronfani, Luca
- Published
- 2021
- Full Text
- View/download PDF
13. Curcumin Anti-Apoptotic Action in a Model of Intestinal Epithelial Inflammatory Damage.
- Author
-
Loganes, Claudia, Bramuzzo, Matteo, Brumatti, Liza Vecchi, Valencic, Erica, Tommasini, Alberto, Lega, Sara, Piscianz, Elisa, and Marcuzzi, Annalisa
- Abstract
The purpose of this study is to determine if a preventive treatment with curcumin can protect intestinal epithelial cells from inflammatory damage induced by IFNγ. To achieve this goal we have used a human intestinal epithelial cell line (HT29) treated with IFNγ to undergo apoptotic changes that can reproduce the damage of intestinal epithelia exposed to inflammatory cytokines. In this model, we measured the effect of curcumin (curcuminoid from Curcuma Longa) added as a pre-treatment at different time intervals before stimulation with IFNγ. Curcumin administration to HT29 culture before the inflammatory stimulus IFNγ reduced the cell apoptosis rate. This effect gradually declined with the reduction of the curcumin pre-incubation time. This anti-apoptotic action by curcumin pre-treatment was paralleled by a reduction of secreted IL7 in the HT29 culture media, while there was no relevant change in the other cytokine levels. Even though curcumin pre-administration did not impact the activation of the NF-γB pathway, a slight effect on the phosphorylation of proteins in this inflammatory signaling pathway was observed. In conclusion, curcumin pre-treatment can protect intestinal cells from inflammatory damage. These results can be the basis for studying the preventive role of curcumin in inflammatory bowel diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. Action of methotrexate and tofacitinib on directly stimulated and bystander-activated lymphocytes.
- Author
-
PISCIANZ, ELISA, CANDILERA, VANESSA, VALENCIC, ERICA, LOGANES, CLAUDIA, PARON, GRETA, IUDICIBUS, SARA DE, DECORTI, GIULIANA, and TOMMASINI, ALBERTO
- Subjects
- *
METHOTREXATE , *RHEUMATIC heart disease , *ANTINEOPLASTIC agents , *PTERIDINES , *MONONUCLEAR leukocytes - Abstract
Chronic inflammation associated with autoimmune activation is characteristic of rheumatic diseases from childhood to adulthood. In recent decades, significant improvements in the treatment of these types of disease have been achieved using disease modifying anti-rheumatic drugs (DMARDs), such as methotrexate (MTX) and, more recently, using biologic inhibitors. The recent introduction of kinase inhibitors (for example, tofacitinib; Tofa) further increases the available ARDs. However, there are patients that do not respond to any treatment strategies, for whom combination therapies are proposed. The data regarding the combined action of different drugs is lacking and the knowledge of the mechanisms of ARDs and their actions upon pathogenic lymphocytes, which are hypothesized to sustain disease, is poor. An in vitro model of inflammation was developed in the current study, in which stimulated and unstimulated lymphocytes were cultured together, but tracked separately, to investigate the action of MTX and Tofa on the two populations. By analysing lymphocyte proliferation and activation, and cytokine secretion in the culture supernatants, it was established that, due to the presence of activated cells, unstimulated cells underwent a bystander activation that was modulated by the ARDs. Additionally, varying administration schedules were demonstrated to affect lymphocytes differently in vitro, either directly or via bystander activation. Furthermore, MTX and Tofa exerted different effects; while MTX showed an antiproliferative effect, Tofa marginally effected activation, although only a slight antiproliferative action, which could be potentiated by sequential treatment with MTX. Thus, it was hypothesized that these differences may be exploited in sequential therapeutic strategies, to maximize the anti-rheumatic effect. These findings are notable and must be accounted for, as bystander-activated cells in vivo could contribute to the spread of autoimmune activation and disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. Putative modifier genes in mevalonate kinase deficiency.
- Author
-
MARCUZZI, ANNALISA, VOZZI, DIEGO, GIRARDELLI, MARTINA, TRICARICO, PAOLA MAURA, KNOWLES, ALESSANDRA, CROVELLA, SERGIO, VUCH, JOSEF, TOMMASINI, ALBERTO, PISCIANZ, ELISA, and BIANCO, ANNA MONICA
- Subjects
MEVALONATE kinase deficiency ,GENOTYPES ,PHENOTYPES ,REGULATOR genes ,DNA - Abstract
Mevalonate kinase deficiency (MKD) is an autosomal recessive auto-inflammatory disease, caused by impairment of the mevalonate pathway. Although the molecular mechanism remains to be elucidated, there is clinical evidence suggesting that other regulatory genes may be involved in determining the phenotype. The identification of novel target genes may explain non-homogeneous genotype-phenotype correlations, and provide evidence in support of the hypothesis that novel regulatory genes predispose or amplify deregulation of the mevalonate pathway in this orphan disease. In the present study, DNA samples were obtained from five patients with MKD, which were then analyzed using whole exome sequencing. A missense variation in the PEX11γ gene was observed in homozygosis in P2, possibly correlating with visual blurring. The UNG rare gene variant was detected in homozygosis in P5, without correlating with a specific clinical phenotype. A number of other variants were found in the five analyzed DNA samples from the MKD patients, however no correlation with the phenotype was established. The results of the presents study suggested that further analysis, using next generation sequencing approaches, is required on a larger sample size of patients with MKD, who share the same MVK mutations and exhibit 'extreme' clinical phenotypes. As MVK mutations may be associated with MKD, the identification of specific modifier genes may assist in providing an earlier diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
16. Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology.
- Author
-
Marcuzzi, Annalisa, Piscianz, Elisa, Zweyer, Marina, Bortul, Roberta, Loganes, Claudia, Girardelli, Martina, Baj, Gabriele, Monasta, Lorenzo, and Celeghini, Claudio
- Subjects
- *
CHOLESTEROL , *APOPTOSIS , *MEVALONATE kinase deficiency , *MITOCHONDRIA , *NEUROLOGICAL disorders - Abstract
Deregulation of the cholesterol pathway is an anomaly observed in human diseases, many of which have in common neurological involvement and unknown pathogenesis. In this study we have used Mevalonate Kinase Deficiency (MKD) as a disease-model in order to investigate the link between the deregulation of the mevalonate pathway and the consequent neurodegeneration. The blocking of the mevalonate pathway in a neuronal cell line (Daoy), using statins or mevalonate, induced an increase in the expression of the inflammasome gene (NLRP3) and programmed cell death related to mitochondrial dysfunction. The morphology of the mitochondria changed, clearly showing the damage induced by oxidative stress and the decreased membrane potential associated with the alterations of the mitochondrial function. The co-administration of geranylgeraniol (GGOH) reduced the inflammatory marker and the damage of the mitochondria, maintaining its shape and components. Our data allow us to speculate about the mechanism by which isoprenoids are able to rescue the inflammatory marker in neuronal cells, independently from the block of the mevalonate pathway, and about the fact that cell death is mitochondria-related. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
17. Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis Pathway.
- Author
-
Marcuzzi, Annalisa, Piscianz, Elisa, Loganes, Claudia, Vecchi Brumatti, Liza, Knowles, Alessandra, Bilel, Sabrine, Tommasini, Alberto, Bortul, Roberta, and Zweyer, Marina
- Subjects
- *
CHOLESTEROL , *INFLAMMATION , *BIOSYNTHESIS , *MITOCHONDRIA , *APOPTOSIS - Abstract
The cholesterol pathway is an essential biochemical process aimed at the synthesis of bioactive molecules involved in multiple crucial cellular functions. The end products of this pathway are sterols, such as cholesterol, which are essential components of cell membranes, precursors of steroid hormones, bile acids and other molecules such as ubiquinone. Several diseases are caused by defects in this metabolic pathway: the most severe forms of which cause neurological involvement (psychomotor retardation and cerebellar ataxia) as a result of a variety of cellular impairments, including mitochondrial dysfunction. These pathologies are induced by convergent mechanisms in which the mitochondrial unit plays a pivotal role contributing to defective apoptosis, autophagy and mitophagy processes. Unraveling these mechanisms would contribute to the development of effective drug treatments for these disorders. In addition, the development of biochemical models could have a substantial impact on the understanding of the mechanism of action of drugs that act on this pathway in multifactor disorders. In this review we will focus in particular on inhibitors of cholesterol synthesis, mitochondria-targeted drugs and inhibitors of the inflammasome. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
18. To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies.
- Author
-
Marcuzzi, Annalisa, Piscianz, Elisa, Valencic, Erica, Monasta, Lorenzo, Brumatti, Liza Vecchi, and Tommasini, Alberto
- Subjects
- *
INFLAMMATION treatment , *CYTOKINES , *ANTI-inflammatory agents , *BIOTHERAPY , *BIOPHARMACEUTICS , *MONOCLONAL antibodies , *RECOMBINANT proteins , *SMALL molecules , *THERAPEUTICS - Abstract
Cytokines are the most important soluble mediators of inflammation. Rare pediatric diseases provided exemplar conditions to study the anti-inflammatory efficacy of new generation therapies (biologics/biopharmaceuticals) selectively targeting single cytokines. Monoclonal antibodies and recombinant proteins have revolutionized anti-inflammatory therapies in the last two decades, allowing the specific targeting of single cytokines. They are very effective in extinguishing inflammation from outside the cell, even with the risk of an excessive and prolonged immunosuppression. Small molecules can enter the cell and shutdown the valve of inflammation by directly targeting signal proteins involved in cytokine release or in response to cytokines. They are orally-administrable drugs whose dosage can be easily adjusted to obtain the desired anti-inflammatory effect. This could make these drugs more suitable for a wide range of diseases as stroke, gout, or neurological impairment, where inflammatory activation plays a pivotal role as trigger. Autoinflammatory diseases, which have previously put anti-cytokine proteins in the limelight, can again provide a valuable model to measure the real potential of small inhibitors as anti-inflammatory agents. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
19. Knockdown of MVK does not lead to changes in NALP3 expression or activation.
- Author
-
Celsi, Fulvio, Piscianz, Elisa, Romano, Maurizio, and Crovella, Sergio
- Subjects
MEVALONATE kinase deficiency ,GENETIC mutation ,ATAXIA ,CEREBELLUM anatomy ,CEREBELLUM abnormalities ,PROTEIN expression ,DISEASE risk factors - Abstract
Background: Mutations in the Mevalonate Kinase gene (MVK) are causes of a rare autoinflammatory disease: Mevalonate Kinase Deficiency and its more acute manifestation, Mevalonic Aciduria. The latter is characterized, among other features, by neuroinflammation, developmental delay and ataxia, due to failed cerebellar development or neuronal death through chronic inflammation. Pathogenesis of neuroinflammation in Mevalonate Kinase Deficiency and Mevalonic Aciduria has not yet been completely clarified, however different research groups have been suggesting the inflammasome complex as the key factor in the disease development. A strategy to mimic this disease is blocking the mevalonate pathway, using HMG-CoA reductase inhibitors (Statins), while knock-out mice for Mevalonate Kinase are non-vital and their hemyzygous (i.e only one copy of gene preserved) littermate display almost no pathological features. Findings: We sought to generate a murine cellular model closely resembling the pathogenic conditions found in vivo, by direct silencing of Mevalonate Kinase gene. Knockdown of Mevalonate Kinase in a murine microglial cellular model (BV-2 cells) results in neither augmented NALP3 expression nor increase of apoptosis. On the contrary, statin treatment of BV-2 cells produces an increase both in Mevalonate Kinase and NALP3 expression. Conclusions: MKD deficiency could be due or affected by protein accumulation leading to NALP3 activation, opening novel questions about strategies to tackle this disease. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
20. Inhibition of mesenchymal stromal cells by pre-activated lymphocytes and their culture media.
- Author
-
Valencic, Erica, Loganes, Claudia, Cesana, Stefania, Piscianz, Elisa, Gaipa, Giuseppe, Biagi, Ettore, and Tommasini, Alberto
- Subjects
LEUCOCYTES ,CELLS ,IMPULSE (Psychology) ,FIRE assay ,KILLER cells ,FLOW cytometry - Abstract
Introduction Despite having a proven immunosuppressive potential in vitro, human mesenchymal stromal cells (MSCs) are reported to display variable efficacy in vivo and, in fact, their proven benefit in the clinical practice is still limited and controversial. Methods The interplay between clinical grade MSCs and pre-activated donor lymphocytes or selected lymphocyte subsets was studied in vitro. The kinetics of MSC growth and viability was evaluated by adhesion-dependent changes of culture plate impedance and biochemically by a colorimetric assay. Activation of natural killer (NK) cells was assessed as well, using a flow cytometry assay. Results A strong inhibition of MSC growth was rapidly induced by the addition of pre-activated lymphocytes but not of resting lymphocytes. Inhibition seems not to be attributable to a single cell population, as similar results can be obtained by depleting NK cells or by using either selected CD4
+ or CD8+ lymphocytes. In addition, conditioned medium (CM) from activated lymphocytes was able to inhibit MSC growth in a dose-dependent manner. Furthermore, licensing with IFN-γ partially protected MSCs from pre-activated lymphocytes but not from their CM. These results suggest an inhibitory role of lymphocyte-activationderived substances. However, the identification of a single molecule responsible for MSC inhibition remained elusive, even if preliminary experiments showed that ATP and, to a lesser extent, TNF-α might play a role. Conclusions These results suggest that survival of MSCs can be affected by soluble mediators released by activated lymphocytes. Thus it can be hypothesized that MSC immunosuppressive action in vivo could be impaired by ongoing immune activation through the release of inflammatory mediators. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
21. Fate of Lymphocytes after Withdrawal of Tofacitinib Treatment.
- Author
-
Piscianz, Elisa, Valencic, Erica, Cuzzoni, Eva, De Iudicibus, Sara, De Lorenzo, Elisa, Decorti, Giuliana, and Tommasini, Alberto
- Subjects
- *
LYMPHOCYTES , *CELL differentiation , *PYRIMIDINES , *T cells , *AUTOIMMUNE disease treatment , *PROTEIN-tyrosine kinases , *GRAFT rejection - Abstract
Tofacitinib (Tofa) is an inhibitor of Janus Kinase 3, developed for the treatment of autoimmune diseases and for the prevention of transplant rejection. Due to its selective action on proliferating cells, Tofa can offer a way to block T cell activation, without toxic effects on resting cells. However, few studies have investigated the effects of Tofa on lymphocyte activation in vitro. Our aim was to study the action of Tofa on different lymphocyte subsets after in vitro stimulation and to track the behaviour of treated cells after interruption of the treatment. Peripheral blood lymphocytes were stimulated in vitro with mitogen and treated with two concentrations of Tofa. After a first period in culture, cells were washed and further incubated for an additional time. Lymphocyte subsets, activation phenotype and proliferation were assessed at the different time frames. As expected, Tofa was able to reduce the activation and proliferation of lymphocytes in the first four days of treatment. In addition the drug led to a relative decrease of Natural Killer, B cells and CD8 T cells compared to CD4 T cells. However, treated cells were still viable after the first period in culture and begun to proliferate, strikingly, in a dose dependent manner when the drug was removed from the environment by replacing the culture medium. This novel data does not necessarily predict a similar behaviour in vivo, but can warn about the clinical use of this drug when a discontinuation of treatment with Tofa is considered for any reason. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
22. Mevalonate Kinase Deficiency and Neuroinflammation: Balance between Apoptosis and Pyroptosis.
- Author
-
Tricarico, Paola Maura, Marcuzzi, Annalisa, Piscianz, Elisa, Monasta, Lorenzo, Crovella, Sergio, and Kleiner, Giulio
- Subjects
MEVALONATE kinase deficiency ,FEVER ,APOPTOSIS ,CYTOKINES ,CENTRAL nervous system - Abstract
Mevalonic aciduria, a rare autosomal recessive disease, represents the most severe form of the periodic fever, known as Mevalonate Kinase Deficiency. This disease is caused by the mutation of the MVK gene, which codes for the enzyme mevalonate kinase, along the cholesterol pathway. Mevalonic aciduria patients show recurrent fever episodes with associated inflammatory symptoms, severe neurologic impairments, or death, in early childhood. The typical neurodegeneration occurring in mevalonic aciduria is linked both to the intrinsic apoptosis pathway (caspase-3 and -9), which is triggered by mitochondrial damage, and to pyroptosis (caspase-1). These cell death mechanisms seem to be also related to the assembly of the inflammasome, which may, in turn, activate pro-inflammatory cytokines and chemokines. Thus, this particular molecular platform may play a crucial role in neuroinflammation mechanisms. Nowadays, a specific therapy is still lacking and the pathogenic mechanisms involving neuroinflammation and neuronal dysfunction have not yet been completely understood, making mevalonic aciduria an orphan drug disease. This review aims to analyze the relationship among neuroinflammation, mitochondrial damage, programmed cell death, and neurodegeneration. Targeting inflammation and degeneration in the central nervous system might help identify promising treatment approaches for mevalonic aciduria or other diseases in which these mechanisms are involved. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
23. Clinical Genetic Testing of Periodic Fever Syndromes.
- Author
-
Marcuzzi, Annalisa, Piscianz, Elisa, Kleiner, Giulio, Tommasini, Alberto, Severini, Giovanni Maria, Monasta, Lorenzo, and Crovella, Sergio
- Abstract
Periodic fever syndromes (PFSs) are a wide group of autoinflammatory diseases. Due to some clinical overlap between different PFSs, differential diagnosis can be a difficult challenge. Nowadays, there are no universally agreed recommendations for most PFSs, and near half of patients may remain without a genetic diagnosis even after performing multiple-gene analyses. Molecular analysis of periodic fevers' causative genes can improve patient quality of life by providing early and accurate diagnosis and allowing the administration of appropriate treatment. In this paper we focus our discussion on effective usefulness of genetic diagnosis of PFSs. The aim of this paper is to establish how much can the diagnostic system improve, in order to increase the success of PFS diagnosis. The mayor expectation in the near future will be addressed to the so-called next generation sequencing approach. Although the application of bioinformatics to high-throughput genetic analysis could allow the identification of complex genotypes, the complexity of this definition will hardly result in a clear contribution for the physician. In our opinion, however, to obtain the best from this new development a rule should always be kept well in mind: use genetics only to answer specific clinical questions. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
24. Temperature and Drug Treatments in Mevalonate Kinase Deficiency: An Ex Vivo Study.
- Author
-
Tricarico, Paola Maura, Kleiner, Giulio, Piscianz, Elisa, Zanin, Valentina, Monasta, Lorenzo, Crovella, Sergio, and Marcuzzi, Annalisa
- Abstract
Mevalonate Kinase Deficiency (MKD) is a rare autosomal recessive inborn disorder of cholesterol biosynthesis caused by mutations in the mevalonate kinase (MK) gene, leading to MK enzyme decreased activity. The consequent shortage of mevalonate-derived isoprenoid compounds results in an inflammatory phenotype, caused by the activation of the NALP3 inflammasome that determines an increased caspase-1 activation and IL-1ß release. In MKD, febrile temperature can further decrease the residual MK activity, leading to mevalonate pathway modulation and to possible disease worsening. We previously demonstrated that the administration of exogenous isoprenoids such as geraniol or the modulation of the enzymatic pathway with drugs, such as Tipifarnib, partially rescues the inflammatory phenotype associated with the defective mevalonic pathway. However, it has not been investigated yet how temperature can affect the success of these treatments. Thus, we investigated the effect of temperature on primary human monocytes from MKD patients. Furthermore the ability of geraniol and Tipifarnib to reduce the abnormal inflammatory response, already described at physiological temperature in MKD, was studied in a febrile condition. We evidenced the role of temperature in the modulation of the inflammatory events and suggested strongly considering this variable in future researches aimed at finding a treatment for MKD. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
25. Lovastatin-induced apoptosis is modulated by geranylgeraniol in a neuroblastoma cell line
- Author
-
Marcuzzi, Annalisa, Zanin, Valentina, Piscianz, Elisa, Tricarico, Paola Maura, Vuch, Josef, Girardelli, Martina, Monasta, Lorenzo, Bianco, Anna Monica, and Crovella, Sergio
- Subjects
LOVASTATIN ,APOPTOSIS ,NEUROBLASTOMA ,CELL lines ,MEVALONATE kinase ,DEFICIENCY diseases ,ISOPENTENOIDS - Abstract
Abstract: Mevalonic aciduria (MA), the most severe form of mevalonate kinase deficiency (MKD), is still an orphan drug disease and the pathogenetic mechanisms underlying neuronal dysfunction is still poorly understood. In our study we have investigated the apoptotic mechanism mediated by the exposure of the cultured neuroblastoma cell line, SH-SY5Y, to lovastatin in absence or in presence of the isoprenoid, geranylgeraniol, with the aim of unraveling the pathogenesis of MA. Lovastatin, blocks the mevalonate pathway inhibiting the 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CR), an enzyme of the mevalonate pathway upstream the mevalonate kinase enzyme, reproducing biochemical features similar to those found in MKD. We demonstrate that apoptosis in neuronal lovastatin treated-cells is induced by the mitochondrial pathway, with caspase-9 as the initiator and caspase-3 as the effector caspase. The presence of geranylgeraniol modulates both the caspase-9 and caspase-3 activity in a dose-dependent way, confirming that this isoprenoid enters the mevalonate pathway, is metabolized and finally is able to by-pass the statin biochemical block reconstituting the mevalonate pathway. According to our findings, it should not be the time course adopted that modulates the apoptotic response but rather the isoprenoid itself. Being aware that our results have been obtained using a biochemical model of MKD, and not cells from patients with the disease, we believe our findings increase the knowledge of MA pathogenesis, and may possibly contribute to the development of novel therapeutic strategies. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
26. Selective resistance to different glucocorticoids in severe autoimmune disorders
- Author
-
Drigo, Ilenia, Piscianz, Elisa, Valencic, Erica, De Iudicibus, Sara, Tommasini, Alberto, Ventura, Alessandro, and Decorti, Giuliana
- Subjects
- *
GLUCOCORTICOIDS , *AUTOIMMUNE diseases , *MULTIDRUG resistance , *GLYCOPROTEINS , *BIOLOGICAL transport , *DRUG activation , *INFLAMMATION - Abstract
Abstract: Resistance to glucocorticoids often occurs in patients with severe inflammatory disorders. Occasionally, this resistance could be overcome by switching to a different glucocorticoid, but the mechanisms of this selectivity are not clear. We studied this condition in three patients with severe inflammatory disorders, who responded satisfactorily to betamethasone, but could not be switched to equipotent doses of methylprednisolone or prednisone. While betamethasone displayed similar activity on lymphocyte proliferation in cells obtained from the three patients and controls, higher concentrations of methylprednisolone were needed to inhibit proliferation in patients'' cells. In a competition study, the concentration of methylprednisolone that inhibited 50% of specific [3H]dexamethasone binding was increased in patients'' lymphocytes. Higher Rhodamine-123 efflux was demonstrated in CD4 T cells from two patients, suggesting that an increased activity of membrane transporters could be responsible for the selective response to different glucocorticoids, even if P-glycoprotein and MRP1 expression was not increased. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
27. MitoQ Is Able to Modulate Apoptosis and Inflammation.
- Author
-
Piscianz, Elisa, Tesser, Alessandra, Rimondi, Erika, Melloni, Elisabetta, Celeghini, Claudio, Marcuzzi, Annalisa, and Scorziello, Antonella
- Subjects
- *
REACTIVE oxygen species , *HOMEOSTASIS , *BIOAVAILABILITY , *INFLAMMATION , *APOPTOSIS , *NEURODEGENERATION - Abstract
Mitoquinone (MitoQ) is a mitochondrial reactive oxygen species scavenger that is characterized by high bioavailability. Prior studies have demonstrated its neuroprotective potential. Indeed, the release of reactive oxygen species due to damage to mitochondrial components plays a pivotal role in the pathogenesis of several neurodegenerative diseases. The present study aimed to examine the impact of the inflammation platform activation on the neuronal cell line (DAOY) treated with specific inflammatory stimuli and whether MitoQ addition can modulate these deregulations. DAOY cells were pre-treated with MitoQ and then stimulated by a blockade of the cholesterol pathway, also called mevalonate pathway, using a statin, mimicking cholesterol deregulation, a common parameter present in some neurodegenerative and autoinflammatory diseases. To verify the role played by MitoQ, we examined the expression of genes involved in the inflammation mechanism and the mitochondrial activity at different time points. In this experimental design, MitoQ showed a protective effect against the blockade of the mevalonate pathway in a short period (12 h) but did not persist for a long time (24 and 48 h). The results obtained highlight the anti-inflammatory properties of MitoQ and open the question about its application as an effective adjuvant for the treatment of the autoinflammatory disease characterized by a cholesterol deregulation pathway that involves mitochondrial homeostasis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
28. Corrigendum to "Tregs and Th17 lymphocytes in human DYRK1A haploinsufficiency" [Immunol. Lett. 214 (2019) 52–54].
- Author
-
Valencic, Erica, Piscianz, Elisa, Sirchia, Fabio, Tommasini, Alberto, Faletra, Flavio, Todaro, Francesca, Spinelli, Alessandro Mauro, and Badolato, Raffaele
- Subjects
- *
SUPPRESSOR cells , *LYMPHOCYTES , *HUMAN beings - Abstract
Lett. Corrigendum to "Tregs and Th17 lymphocytes in human DYRK1A haploinsufficiency" [Immunol. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
29. Priming of the cGAS-STING-TBK1 Pathway Enhances LPS-Induced Release of Type I Interferons.
- Author
-
Tesser, Alessandra, Piperno, Giulia Maria, Pin, Alessia, Piscianz, Elisa, Boz, Valentina, Benvenuti, Federica, Tommasini, Alberto, and Schmidt-Arras, Dirk
- Subjects
TYPE I interferons ,SYSTEMIC lupus erythematosus ,NUCLEIC acids ,TOLL-like receptors ,DENDRITIC cells ,BONE cells - Abstract
Cytoplasmic nucleic acids sensing through cGAS-STING-TBK1 pathway is crucial for the production of antiviral interferons (IFNs). IFN production can also be induced by lipopolysaccharide (LPS) stimulation through Toll-like receptor 4 (TLR4) in appropriate conditions. Of note, both IFN production and dysregulated LPS-response could play a role in the pathogenesis of Systemic Lupus Erythematosus (SLE). Indeed, LPS can trigger SLE in lupus-prone mice and bacterial infections can induce disease flares in human SLE. However, the interactions between cGAS and TLR4 pathways to IFNs have been poorly investigated. To address this issue, we studied LPS-stimulation in cellular models with a primed cGAS-STING-TBK1 pathway. cGAS-stimulation was naturally sustained by undigested self-nucleic acids in fibroblasts from DNase2-deficiency interferonopathy, whilst it was pharmacologically obtained by cGAMP-stimulation in THP1 cells and murine bone marrow-derived dendritic cells. We showed that cells with a primed cGAS-STING-TBK1 pathway displayed enhanced IFNs production after TLR4-challenge. STING-inhibition did not affect IFN production after LPS alone, but prevented the amplified IFN production in cGAMP-primed cells, suggesting that functional STING is required for priming-dependent enhancement. Furthermore, we speculated that an increased PIK3AP1 expression in DNase2-deficient fibroblasts may link cGAMP-priming with increased LPS-induced IFN production. We showed that both the hyper-expression of PIK3API and the enhanced LPS-induced IFN production can be contrasted by STING inhibitors. Our results may explain how bacterial LPS can synergize with cGAS-pathway in promoting the development of SLE-like autoimmunity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Immunity and Genetics at the Revolving Doors of Diagnostics in Primary Immunodeficiencies.
- Author
-
Rispoli, Francesco, Valencic, Erica, Girardelli, Martina, Pin, Alessia, Tesser, Alessandra, Piscianz, Elisa, Boz, Valentina, Faletra, Flavio, Severini, Giovanni Maria, Taddio, Andrea, Tommasini, Alberto, and Amoroso, Antonio
- Subjects
GENETICS ,DISEASE relapse ,GENETIC testing ,PHENOTYPES ,IMMUNITY ,AGAMMAGLOBULINEMIA ,PRIMARY immunodeficiency diseases - Abstract
Primary immunodeficiencies (PIDs) are a large and growing group of disorders commonly associated with recurrent infections. However, nowadays, we know that PIDs often carry with them consequences related to organ or hematologic autoimmunity, autoinflammation, and lymphoproliferation in addition to simple susceptibility to pathogens. Alongside this conceptual development, there has been technical advancement, given by the new but already established diagnostic possibilities offered by new genetic testing (e.g., next-generation sequencing). Nevertheless, there is also the need to understand the large number of gene variants detected with these powerful methods. That means advancing beyond genetic results and resorting to the clinical phenotype and to immunological or alternative molecular tests that allow us to prove the causative role of a genetic variant of uncertain significance and/or better define the underlying pathophysiological mechanism. Furthermore, because of the rapid availability of results, laboratory immunoassays are still critical to diagnosing many PIDs, even in screening settings. Fundamental is the integration between different specialties and the development of multidisciplinary and flexible diagnostic workflows. This paper aims to tell these evolving aspects of immunodeficiencies, which are summarized in five key messages, through introducing and exemplifying five clinical cases, focusing on diseases that could benefit targeted therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Gene Expression Analysis of Mevalonate Kinase Deficiency Affected Children Identifies Molecular Signatures Related to Hematopoiesis.
- Author
-
Pisanti, Simona, Citro, Marianna, Abate, Mario, Caputo, Mariella, Martinelli, Rosanna, Marcuzzi, Annalisa, Melloni, Elisabetta, and Piscianz, Elisa
- Published
- 2021
- Full Text
- View/download PDF
32. An Easy and Reliable Strategy for Making Type I Interferon Signature Analysis Comparable among Research Centers.
- Author
-
Pin, Alessia, Monasta, Lorenzo, Taddio, Andrea, Piscianz, Elisa, Tommasini, Alberto, and Tesser, Alessandra
- Subjects
TYPE I interferons ,SYSTEMIC lupus erythematosus ,RESEARCH institutes - Abstract
Interferon-stimulated genes (ISGs) are a set of genes whose transcription is induced by interferon (IFN). The measure of the expression of ISGs enables calculating an IFN score, which gives an indirect estimate of the exposition of cells to IFN-mediated inflammation. The measure of the IFN score is proposed for the screening of monogenic interferonopathies, like the Aicardi-Goutières syndrome, or to stratify subjects with systemic lupus erythematosus to receive IFN-targeted treatments. Apart from these scenarios, there is no agreement on the diagnostic value of the score in distinguishing IFN-related disorders from diseases dominated by other types of cytokines. Since the IFN score is currently measured in several research hospitals, merging experiences could help define the potential of scoring IFN inflammation in clinical practice. However, the IFN score calculated at different laboratories may be hardly comparable due to the distinct sets of IFN-stimulated genes assessed and to different controls used for data normalization. We developed a reliable approach to minimize the inter-laboratory variability, thereby providing shared strategies for the IFN signature analysis and allowing different centers to compare data and merge their experiences. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
33. The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases.
- Author
-
Bernardi, Stella, Marcuzzi, Annalisa, Piscianz, Elisa, Tommasini, Alberto, and Fabris, Bruno
- Subjects
LIPID analysis ,INFLAMMATION ,INTERLEUKINS ,GROWTH factors ,CARDIOVASCULAR diseases - Abstract
Lipids and inflammation regulate each other. Early studies on this topic focused on the systemic effects that the acute inflammatory response—and interleukins—had on lipid metabolism. Today, in the era of the obesity epidemic, whose primary complications are cardio-metabolic diseases, attention has moved to the effects that the nutritional environment and lipid derangements have on peripheral tissues, where lipotoxicity leads to organ damage through an imbalance of chronic inflammatory responses. After an overview of the effects that acute inflammation has on the systemic lipid metabolism, this review will describe the lipid-induced immune responses that take place in peripheral tissues and lead to chronic cardio-metabolic diseases. Moreover, the anti-inflammatory effects of lipid lowering drugs, as well as the possibility of using anti-inflammatory agents against cardio-metabolic diseases, will be discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
34. Neuronal Dysfunction Associated with Cholesterol Deregulation.
- Author
-
Marcuzzi, Annalisa, Loganes, Claudia, Valencic, Erica, Piscianz, Elisa, Monasta, Lorenzo, Bilel, Sabrine, Bortul, Roberta, Celeghini, Claudio, Zweyer, Marina, and Tommasini, Alberto
- Subjects
CHOLESTEROL metabolism ,BIOSYNTHESIS ,APOPTOSIS ,NEURONS ,MITOCHONDRIA - Abstract
Cholesterol metabolism is crucial for cells and, in particular, its biosynthesis in the central nervous system occurs in situ, and its deregulation involves morphological changes that cause functional variations and trigger programmed cell death. The pathogenesis of rare diseases, such as Mevalonate Kinase Deficiency or Smith–Lemli–Opitz Syndrome, arises due to enzymatic defects in the cholesterol metabolic pathways, resulting in a shortage of downstream products. The most severe clinical manifestations of these diseases appear as neurological defects. Expanding the knowledge of this biological mechanism will be useful for identifying potential targets and preventing neuronal damage. Several studies have demonstrated that deregulation of the cholesterol pathway induces mitochondrial dysfunction as the result of respiratory chain damage. We set out to determine whether mitochondrial damage may be prevented by using protective mitochondria-targeted compounds, such as MitoQ, in a neuronal cell line treated with a statin to induce a biochemical block of the cholesterol pathway. Evidence from the literature suggests that mitochondria play a crucial role in the apoptotic mechanism secondary to blocking the cholesterol pathway. Our study shows that MitoQ, administered as a preventive agent, could counteract the cell damage induced by statins in the early stages, but its protective role fades over time. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
35. Tregs and Th17 lymphocytes in human DYRK1A haploinsufficiency.
- Author
-
Todaro, Francesca, Spinelli, Alessandro Mauro, Badolato, Raffaele, Valencic, Erica, Piscianz, Elisa, Sirchia, Fabio, Tommasini, Alberto, and Faletra, Flavio
- Subjects
- *
SUPPRESSOR cells , *LYMPHOCYTES , *T helper cells , *TH1 cells , *B cells , *INTERLEUKIN-27 , *INTERLEUKIN-9 - Published
- 2019
- Full Text
- View/download PDF
36. Altered germinal center reaction and abnormal B cell peripheral maturation in PI3KR1-mutated patients presenting with HIGM-like phenotype.
- Author
-
Lougaris, Vassilios, Faletra, Flavio, Lanzi, Gaetana, Vozzi, Diego, Marcuzzi, Annalisa, Valencic, Erica, Piscianz, Elisa, Bianco, AnnaMonica, Girardelli, Martina, Baronio, Manuela, Loganes, Claudia, Fasth, Anders, Salvini, Filippo, Trizzino, Antonino, Moratto, Daniele, Facchetti, Fabio, Giliani, Silvia, Plebani, Alessandro, and Tommasini, Alberto
- Subjects
- *
GERMINAL centers , *B cells , *PHOSPHATIDYLINOSITOL 3-kinases , *PHENOTYPES , *IMMUNOGLOBULIN M - Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.